Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 09, 2025 | June 11, 2025 |
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| ELUTIA INC.ELUT · Entity 7342 | Director | June 11, 2026 | June 15, 2026 |
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Director | April 03, 2019 | April 03, 2019 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 09, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,743 |
Reported balance
After 2025-06-09 transaction · row 1
1 source rowRow 1 · 2025-06-09 · Sale · Disposed 4,073 · Balance 86,743 F1: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 117,523 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 117,523 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
ELUTIA INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2036-06-11 | Direct | 106,393 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 106,393 · Balance 106,393 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
ENDOLOGIX INC /DE/
Report date April 03, 2019 · Filed April 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,200 |
Reported balance
After 2019-04-03 transaction · row 1
1 source rowRow 1 · 2019-04-03 · Purchase · Acquired 22,692 · Balance 43,200 |
TELA Bio, Inc.
Report date June 09, 2026 · Filed June 11, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENTELLUS MEDICAL INC
Report date February 28, 2018 · Filed March 01, 2018
Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2024-12-16 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 106,393 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001222362-26-000013 · form4-06152026_050603.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,393 Underlying: Class A Common Stock · 106,393 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 17,335 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001222362-26-000010 · form4-06112026_100640.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,335 Underlying: Common Stock · 17,335 shares Expires 2036-06-09 F4 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 17,550 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001222362-26-000010 · form4-06112026_100640.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2036-06-09 F3 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 11,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000010 · form4-06112026_100640.xml · nonDerivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,600 F2 · shares: These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 22:07 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 11,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000010 · form4-06112026_100640.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,925 F1 · shares: These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000008 · wk-form4_1780606035.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000008 · wk-form4_1780606035.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:47 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000008 · wk-form4_1780606035.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 13:43 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 20,000 | $1.04 | $20,800.00 |
DisclosureSEC source: 0001222362-26-000004 · form4-02022026_010244.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.07. The reporting person undertakes to provide Elutia Inc. ( the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 29, 2026 Filed Jan 29, 2026 22:51 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 15,000 | $1.06 | $15,900.00 |
DisclosureSEC source: 0001222362-26-000002 · form4-01292026_100111.xml · nonDerivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,750 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.03 to $1.10. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 22:51 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 15,000 | $1.06 | $15,900.00 |
DisclosureSEC source: 0001222362-26-000002 · form4-01292026_100111.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.10. The reporting person undertakes to provide Elutia Inc. ( the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2025 Filed Apr 14, 2026 12:08 UTC | ELUTIA INC. ELUT · Entity 7342 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-26-000006 · form4-04142026_120452.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On March 5, 2025, the Reporting Person was granted 25,000 restricted stock units which vest in four equal installments on March 10, 2025, June 10, 2025, September 10 2025 and December 10, 2025. F3 · derivative.expiration_date: On March 5, 2025, the Reporting Person was granted 25,000 restricted stock units which vest in four equal installments on March 10, 2025, June 10, 2025, September 10 2025 and December 10, 2025. Read SEC document |
| December 10, 2025 Filed Apr 14, 2026 12:08 UTC | ELUTIA INC. ELUT · Entity 7342 | Exercise / conversionClass A Common Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001222362-26-000006 · form4-04142026_120452.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 22:00 UTC | ELUTIA INC. ELUT · Entity 7342 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001222362-25-000009 · form4-12022025_051201.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On December 20, 2023, the Reporting Person was granted 50,000 restricted stock units which vest in eight equal installments on March 1, 2024, June 1, 2024, September 1, 2024, December 1, 2024, March 1, 2025, June 1, 2025, September 1, 2025 and December 1, 2025. F3 · derivative.expiration_date: On December 20, 2023, the Reporting Person was granted 50,000 restricted stock units which vest in eight equal installments on March 1, 2024, June 1, 2024, September 1, 2024, December 1, 2024, March 1, 2025, June 1, 2025, September 1, 2025 and December 1, 2025. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 22:00 UTC | ELUTIA INC. ELUT · Entity 7342 | Exercise / conversionClass A Common Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001222362-25-000009 · form4-12022025_051201.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 13:27 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 171,916 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001222362-25-000007 · form4-10142025_011021.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,916 Underlying: Class A Common Stock · 171,916 shares Expires 2035-10-09 F1 · derivative.exercise_date: The option vests annually in three equal installments of one-third each, on each of the first three anniversaries of the grant date, such that the option shall be fully vested and exercisable on October 9, 2028. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:24 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,073 | $10.61 | $43,214.53 |
DisclosureSEC source: 0000805928-25-000082 · wk-form4_1749673449.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,743 F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000307 · wk-form4_1749087015.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000307 · wk-form4_1749087015.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000307 · wk-form4_1749087015.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 01:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000120 · wk-form4_1725497999.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 01:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000120 · wk-form4_1725497999.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:27 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000288 · wk-form4_1718314032.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000269 · wk-form4_1718153150.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000269 · wk-form4_1718153150.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0000805928-24-000093 · wk-form4_1718057618.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:13 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 10,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000805928-24-000093 · wk-form4_1718057618.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,912 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:24 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000108 · wf-form4_169408226866836.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:24 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000108 · wf-form4_169408226866836.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:12 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 10,000 | $6.11 | $61,100.00 |
DisclosureSEC source: 0000805928-23-000099 · wf-form4_169238951009652.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,259 Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 23:32 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000041 · primary_doc.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:32 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000041 · primary_doc.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:32 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000041 · primary_doc.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000064 · wf-form4_168600551404884.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:52 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000064 · wf-form4_168600551404884.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| June 17, 2022 Filed Jun 23, 2022 00:38 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023637 · doc4.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Common Stock · 6,459 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 11,811 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,811 Underlying: Common Stock · 11,811 shares Expires 2032-06-01 F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000064 · wf-form4_165428692328229.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:12 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013957 · doc4.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on April 1, 2022. F2 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:12 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 2,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013957 · doc4.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:33 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006552 · doc4.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:33 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006552 · doc4.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000108 · wf-form4_162275473035646.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,036 Underlying: Common Stock · 3,036 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 6,030 | $0.00 Strike: $19.76 | $0.00 |
DisclosureSEC source: 0000805928-21-000108 · wf-form4_162275473035646.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,030 Underlying: Common Stock · 6,030 shares Expires 2031-06-01 F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000108 · wf-form4_162275473035646.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. F2 · derivative.expiration_date: This reflects the number of restricted stock units that became vested as of June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:12 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000108 · wf-form4_162275473035646.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $5.09 Strike: $5.09 | $76,350.00 |
DisclosureSEC source: 0000805928-21-000096 · wf-form4_162162845853460.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 31, 2016 (1 year from the option grant date) based upon a vesting schedule whereby 25% of the total shares vested at the end of each fiscal quarter. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $3.80 Strike: $3.80 | $95,000.00 |
DisclosureSEC source: 0000805928-21-000096 · wf-form4_162162845853460.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on August 26, 2017 (2 years from the option grant date) based upon a vesting schedule whereby 12.5% of total shares vested at the end of each fiscal quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.